People · Operator
Named in public records as an officer, director or promoter · active 2013–2026 · Pharmaceuticals, Other Technology, Biotech / Pharma, Biotechnology, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Rx Redefined Inc. | — | Pharmaceuticals | Series B | $35.7M | $126.1M | 2021 |
| Valid8 Financial, Inc. | — | Other Technology | Series A | $18.3M | $20.4M | 2025 |
| AllVoices Holding Co. | — | Other Technology | Series A | $16.7M | $9.7M | 2021 |
| Onyx Bio, Inc. | — | Biotech / Pharma | Series A | $13.3M | $19.6M | 2022 |
| DocJuris Inc. | — | Other Technology | Series A | $12.8M | $34.2M | 2024 |
| Mechademy Inc | — | Other Technology | Series A | $12.2M | $29.1M | 2025 |
| Genia Technologies, Inc. | — | Biotechnology | Series A | $10.4M | $377.4M | 2013 |
| AllVoices Holding Co. | Director | Other Technology | Series A | $7.0M | $17.3M | 2026 |
| Datamined LLC | — | Other Technology | Series A | $4.3M | $120.7M | 2018 |
| MobiTech International Inc. | — | Other Technology | Series A | $4.3M | $116.5M | 2019 |
| Modicus Prime Ltd. | — | Other Health Care | Seed | $3.4M | $15.1M | 2024 |
Roger Chen at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Roger Chen on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.